second generation car t cell therapies targeting cd19 Search Results


cd19 car t cells  (Cell Therapy Ltd)
90
Cell Therapy Ltd cd19 car t cells
FMC63 and HI19α had different binding epitopes on <t>CD19.</t> a Homology models of hCD19 ECD (left), FMC63 scFv (middle), and HI19α scFv (right). b Docking mode of FMC63 and hCD19 ECD. Green, hCD19 ECD epitopes; purple, FMC63 epitopes. c Docking mode of HI19α and hCD19 ECD. Green, hCD19 ECD epitopes; purple, HI19α epitopes. d Sequence of hCD19 ECD. Gray background, predicted binding amino acid residues on hCD19 ECD with scFvs. Upper panel, interaction with HI19α; lower panel, interaction with FMC63. Red color, shared antigen epitopes; yellow color, key epitopes; green color, both shared antigen epitopes and key epitopes. e Partial interaction modes showed the non-bond interaction between scFvs and hCD19 ECD. Upper panel, HI19α scFv and hCD19 ECD; lower panel, FMC63 scFv and hCD19 ECD. Green, hCD19 ECD epitopes; purple, scFvs epitopes. f Flow cytometry analysis of the proportion of CD19 + Nalm-6 cells stained with indicated concentrations of the antibody. Left panel, HI19α antibody; right panel, FMC63 antibody. g Representative flow cytometry analysis showing the proportion of CD19 + cells on Nalm-6 cells stained with 0.017 pM HI19α and 0.042 pM FMC63
Cd19 Car T Cells, supplied by Cell Therapy Ltd, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/second+generation+car+t+cell+therapies+targeting+cd19/cd19+cart+cells/pmc07487702-106-1-9
Average 90 stars, based on 1 article reviews
cd19 car t cells - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier
revolutionary anti cd19 car t cell therapies  (Gilead Sciences)
99
Gilead Sciences revolutionary anti cd19 car t cell therapies
FMC63 and HI19α had different binding epitopes on <t>CD19.</t> a Homology models of hCD19 ECD (left), FMC63 scFv (middle), and HI19α scFv (right). b Docking mode of FMC63 and hCD19 ECD. Green, hCD19 ECD epitopes; purple, FMC63 epitopes. c Docking mode of HI19α and hCD19 ECD. Green, hCD19 ECD epitopes; purple, HI19α epitopes. d Sequence of hCD19 ECD. Gray background, predicted binding amino acid residues on hCD19 ECD with scFvs. Upper panel, interaction with HI19α; lower panel, interaction with FMC63. Red color, shared antigen epitopes; yellow color, key epitopes; green color, both shared antigen epitopes and key epitopes. e Partial interaction modes showed the non-bond interaction between scFvs and hCD19 ECD. Upper panel, HI19α scFv and hCD19 ECD; lower panel, FMC63 scFv and hCD19 ECD. Green, hCD19 ECD epitopes; purple, scFvs epitopes. f Flow cytometry analysis of the proportion of CD19 + Nalm-6 cells stained with indicated concentrations of the antibody. Left panel, HI19α antibody; right panel, FMC63 antibody. g Representative flow cytometry analysis showing the proportion of CD19 + cells on Nalm-6 cells stained with 0.017 pM HI19α and 0.042 pM FMC63
Revolutionary Anti Cd19 Car T Cell Therapies, supplied by Gilead Sciences, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/second+generation+car+t+cell+therapies+targeting+cd19/Yescarta/pmc07521121-1-5-12
Average 99 stars, based on 1 article reviews
revolutionary anti cd19 car t cell therapies - by Bioz Stars, 2026-10
99/100 stars
  Buy from Supplier
cd19 directed car t cell therapy  (Novartis)
86
Novartis cd19 directed car t cell therapy
FMC63 and HI19α had different binding epitopes on <t>CD19.</t> a Homology models of hCD19 ECD (left), FMC63 scFv (middle), and HI19α scFv (right). b Docking mode of FMC63 and hCD19 ECD. Green, hCD19 ECD epitopes; purple, FMC63 epitopes. c Docking mode of HI19α and hCD19 ECD. Green, hCD19 ECD epitopes; purple, HI19α epitopes. d Sequence of hCD19 ECD. Gray background, predicted binding amino acid residues on hCD19 ECD with scFvs. Upper panel, interaction with HI19α; lower panel, interaction with FMC63. Red color, shared antigen epitopes; yellow color, key epitopes; green color, both shared antigen epitopes and key epitopes. e Partial interaction modes showed the non-bond interaction between scFvs and hCD19 ECD. Upper panel, HI19α scFv and hCD19 ECD; lower panel, FMC63 scFv and hCD19 ECD. Green, hCD19 ECD epitopes; purple, scFvs epitopes. f Flow cytometry analysis of the proportion of CD19 + Nalm-6 cells stained with indicated concentrations of the antibody. Left panel, HI19α antibody; right panel, FMC63 antibody. g Representative flow cytometry analysis showing the proportion of CD19 + cells on Nalm-6 cells stained with 0.017 pM HI19α and 0.042 pM FMC63
Cd19 Directed Car T Cell Therapy, supplied by Novartis, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/second+generation+car+t+cell+therapies+targeting+cd19/car+cd19+gegen+gerichtete+insbesondere+t+tisagenlecleucel+wie+zellen/sec_filing____1114448_slash_000104746918000380_slash_a2234185z20___f-845-13-0
Average 86 stars, based on 1 article reviews
cd19 directed car t cell therapy - by Bioz Stars, 2026-10
86/100 stars
  Buy from Supplier
vivo rpe65 leber congenital amaurosis  (Gilead Sciences)
99
Gilead Sciences vivo rpe65 leber congenital amaurosis
FMC63 and HI19α had different binding epitopes on <t>CD19.</t> a Homology models of hCD19 ECD (left), FMC63 scFv (middle), and HI19α scFv (right). b Docking mode of FMC63 and hCD19 ECD. Green, hCD19 ECD epitopes; purple, FMC63 epitopes. c Docking mode of HI19α and hCD19 ECD. Green, hCD19 ECD epitopes; purple, HI19α epitopes. d Sequence of hCD19 ECD. Gray background, predicted binding amino acid residues on hCD19 ECD with scFvs. Upper panel, interaction with HI19α; lower panel, interaction with FMC63. Red color, shared antigen epitopes; yellow color, key epitopes; green color, both shared antigen epitopes and key epitopes. e Partial interaction modes showed the non-bond interaction between scFvs and hCD19 ECD. Upper panel, HI19α scFv and hCD19 ECD; lower panel, FMC63 scFv and hCD19 ECD. Green, hCD19 ECD epitopes; purple, scFvs epitopes. f Flow cytometry analysis of the proportion of CD19 + Nalm-6 cells stained with indicated concentrations of the antibody. Left panel, HI19α antibody; right panel, FMC63 antibody. g Representative flow cytometry analysis showing the proportion of CD19 + cells on Nalm-6 cells stained with 0.017 pM HI19α and 0.042 pM FMC63
Vivo Rpe65 Leber Congenital Amaurosis, supplied by Gilead Sciences, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/second+generation+car+t+cell+therapies+targeting+cd19/Tecartus/pm36284069-68-118-144
Average 99 stars, based on 1 article reviews
vivo rpe65 leber congenital amaurosis - by Bioz Stars, 2026-10
99/100 stars
  Buy from Supplier
cd19-antibody-based car-t therapeutics  (AbClon Inc)
90
AbClon Inc cd19-antibody-based car-t therapeutics
FMC63 and HI19α had different binding epitopes on <t>CD19.</t> a Homology models of hCD19 ECD (left), FMC63 scFv (middle), and HI19α scFv (right). b Docking mode of FMC63 and hCD19 ECD. Green, hCD19 ECD epitopes; purple, FMC63 epitopes. c Docking mode of HI19α and hCD19 ECD. Green, hCD19 ECD epitopes; purple, HI19α epitopes. d Sequence of hCD19 ECD. Gray background, predicted binding amino acid residues on hCD19 ECD with scFvs. Upper panel, interaction with HI19α; lower panel, interaction with FMC63. Red color, shared antigen epitopes; yellow color, key epitopes; green color, both shared antigen epitopes and key epitopes. e Partial interaction modes showed the non-bond interaction between scFvs and hCD19 ECD. Upper panel, HI19α scFv and hCD19 ECD; lower panel, FMC63 scFv and hCD19 ECD. Green, hCD19 ECD epitopes; purple, scFvs epitopes. f Flow cytometry analysis of the proportion of CD19 + Nalm-6 cells stained with indicated concentrations of the antibody. Left panel, HI19α antibody; right panel, FMC63 antibody. g Representative flow cytometry analysis showing the proportion of CD19 + cells on Nalm-6 cells stained with 0.017 pM HI19α and 0.042 pM FMC63
Cd19 Antibody Based Car T Therapeutics, supplied by AbClon Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/second+generation+car+t+cell+therapies+targeting+cd19/cd19+antibody+based+car+t+therapeutics/us11708409-2-39-43
Average 90 stars, based on 1 article reviews
cd19-antibody-based car-t therapeutics - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier
anti-cd19 car-t cell therapy  (Intrexon Inc)
90
Intrexon Inc anti-cd19 car-t cell therapy
FMC63 and HI19α had different binding epitopes on <t>CD19.</t> a Homology models of hCD19 ECD (left), FMC63 scFv (middle), and HI19α scFv (right). b Docking mode of FMC63 and hCD19 ECD. Green, hCD19 ECD epitopes; purple, FMC63 epitopes. c Docking mode of HI19α and hCD19 ECD. Green, hCD19 ECD epitopes; purple, HI19α epitopes. d Sequence of hCD19 ECD. Gray background, predicted binding amino acid residues on hCD19 ECD with scFvs. Upper panel, interaction with HI19α; lower panel, interaction with FMC63. Red color, shared antigen epitopes; yellow color, key epitopes; green color, both shared antigen epitopes and key epitopes. e Partial interaction modes showed the non-bond interaction between scFvs and hCD19 ECD. Upper panel, HI19α scFv and hCD19 ECD; lower panel, FMC63 scFv and hCD19 ECD. Green, hCD19 ECD epitopes; purple, scFvs epitopes. f Flow cytometry analysis of the proportion of CD19 + Nalm-6 cells stained with indicated concentrations of the antibody. Left panel, HI19α antibody; right panel, FMC63 antibody. g Representative flow cytometry analysis showing the proportion of CD19 + cells on Nalm-6 cells stained with 0.017 pM HI19α and 0.042 pM FMC63
Anti Cd19 Car T Cell Therapy, supplied by Intrexon Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/second+generation+car+t+cell+therapies+targeting+cd19/anti+cd19+car+t+cell+therapy/us11427638-830-40-45
Average 90 stars, based on 1 article reviews
anti-cd19 car-t cell therapy - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier
cd19-car-t therapy  (Immunochina Pharmaceuticals Co Ltd)
90
Immunochina Pharmaceuticals Co Ltd cd19-car-t therapy
FMC63 and HI19α had different binding epitopes on <t>CD19.</t> a Homology models of hCD19 ECD (left), FMC63 scFv (middle), and HI19α scFv (right). b Docking mode of FMC63 and hCD19 ECD. Green, hCD19 ECD epitopes; purple, FMC63 epitopes. c Docking mode of HI19α and hCD19 ECD. Green, hCD19 ECD epitopes; purple, HI19α epitopes. d Sequence of hCD19 ECD. Gray background, predicted binding amino acid residues on hCD19 ECD with scFvs. Upper panel, interaction with HI19α; lower panel, interaction with FMC63. Red color, shared antigen epitopes; yellow color, key epitopes; green color, both shared antigen epitopes and key epitopes. e Partial interaction modes showed the non-bond interaction between scFvs and hCD19 ECD. Upper panel, HI19α scFv and hCD19 ECD; lower panel, FMC63 scFv and hCD19 ECD. Green, hCD19 ECD epitopes; purple, scFvs epitopes. f Flow cytometry analysis of the proportion of CD19 + Nalm-6 cells stained with indicated concentrations of the antibody. Left panel, HI19α antibody; right panel, FMC63 antibody. g Representative flow cytometry analysis showing the proportion of CD19 + cells on Nalm-6 cells stained with 0.017 pM HI19α and 0.042 pM FMC63
Cd19 Car T Therapy, supplied by Immunochina Pharmaceuticals Co Ltd, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/second+generation+car+t+cell+therapies+targeting+cd19/im19+car+t+cells/pmc07168573-7140-48-16
Average 90 stars, based on 1 article reviews
cd19-car-t therapy - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier
anti-cd19 antibodies  (MorphoSys ag)
90
MorphoSys ag anti-cd19 antibodies
FMC63 and HI19α had different binding epitopes on <t>CD19.</t> a Homology models of hCD19 ECD (left), FMC63 scFv (middle), and HI19α scFv (right). b Docking mode of FMC63 and hCD19 ECD. Green, hCD19 ECD epitopes; purple, FMC63 epitopes. c Docking mode of HI19α and hCD19 ECD. Green, hCD19 ECD epitopes; purple, HI19α epitopes. d Sequence of hCD19 ECD. Gray background, predicted binding amino acid residues on hCD19 ECD with scFvs. Upper panel, interaction with HI19α; lower panel, interaction with FMC63. Red color, shared antigen epitopes; yellow color, key epitopes; green color, both shared antigen epitopes and key epitopes. e Partial interaction modes showed the non-bond interaction between scFvs and hCD19 ECD. Upper panel, HI19α scFv and hCD19 ECD; lower panel, FMC63 scFv and hCD19 ECD. Green, hCD19 ECD epitopes; purple, scFvs epitopes. f Flow cytometry analysis of the proportion of CD19 + Nalm-6 cells stained with indicated concentrations of the antibody. Left panel, HI19α antibody; right panel, FMC63 antibody. g Representative flow cytometry analysis showing the proportion of CD19 + cells on Nalm-6 cells stained with 0.017 pM HI19α and 0.042 pM FMC63
Anti Cd19 Antibodies, supplied by MorphoSys ag, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/second+generation+car+t+cell+therapies+targeting+cd19/monjuvi/pm39319495-0-11-4
Average 90 stars, based on 1 article reviews
anti-cd19 antibodies - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier
anti cd19 car t cell therapy infusion  (Cell Signaling Technology Inc)
96
Cell Signaling Technology Inc anti cd19 car t cell therapy infusion
FMC63 and HI19α had different binding epitopes on <t>CD19.</t> a Homology models of hCD19 ECD (left), FMC63 scFv (middle), and HI19α scFv (right). b Docking mode of FMC63 and hCD19 ECD. Green, hCD19 ECD epitopes; purple, FMC63 epitopes. c Docking mode of HI19α and hCD19 ECD. Green, hCD19 ECD epitopes; purple, HI19α epitopes. d Sequence of hCD19 ECD. Gray background, predicted binding amino acid residues on hCD19 ECD with scFvs. Upper panel, interaction with HI19α; lower panel, interaction with FMC63. Red color, shared antigen epitopes; yellow color, key epitopes; green color, both shared antigen epitopes and key epitopes. e Partial interaction modes showed the non-bond interaction between scFvs and hCD19 ECD. Upper panel, HI19α scFv and hCD19 ECD; lower panel, FMC63 scFv and hCD19 ECD. Green, hCD19 ECD epitopes; purple, scFvs epitopes. f Flow cytometry analysis of the proportion of CD19 + Nalm-6 cells stained with indicated concentrations of the antibody. Left panel, HI19α antibody; right panel, FMC63 antibody. g Representative flow cytometry analysis showing the proportion of CD19 + cells on Nalm-6 cells stained with 0.017 pM HI19α and 0.042 pM FMC63
Anti Cd19 Car T Cell Therapy Infusion, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/second+generation+car+t+cell+therapies+targeting+cd19/CD19+Antibody/pmc07431616-114-5-19
Average 96 stars, based on 1 article reviews
anti cd19 car t cell therapy infusion - by Bioz Stars, 2026-10
96/100 stars
  Buy from Supplier
autologous cd19 car-t cell therapy  (Curocell Inc)
90
Curocell Inc autologous cd19 car-t cell therapy
FMC63 and HI19α had different binding epitopes on <t>CD19.</t> a Homology models of hCD19 ECD (left), FMC63 scFv (middle), and HI19α scFv (right). b Docking mode of FMC63 and hCD19 ECD. Green, hCD19 ECD epitopes; purple, FMC63 epitopes. c Docking mode of HI19α and hCD19 ECD. Green, hCD19 ECD epitopes; purple, HI19α epitopes. d Sequence of hCD19 ECD. Gray background, predicted binding amino acid residues on hCD19 ECD with scFvs. Upper panel, interaction with HI19α; lower panel, interaction with FMC63. Red color, shared antigen epitopes; yellow color, key epitopes; green color, both shared antigen epitopes and key epitopes. e Partial interaction modes showed the non-bond interaction between scFvs and hCD19 ECD. Upper panel, HI19α scFv and hCD19 ECD; lower panel, FMC63 scFv and hCD19 ECD. Green, hCD19 ECD epitopes; purple, scFvs epitopes. f Flow cytometry analysis of the proportion of CD19 + Nalm-6 cells stained with indicated concentrations of the antibody. Left panel, HI19α antibody; right panel, FMC63 antibody. g Representative flow cytometry analysis showing the proportion of CD19 + cells on Nalm-6 cells stained with 0.017 pM HI19α and 0.042 pM FMC63
Autologous Cd19 Car T Cell Therapy, supplied by Curocell Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/second+generation+car+t+cell+therapies+targeting+cd19/autologous+cd19+car+t+cell+therapy/pmc09429973-3122-41-30
Average 90 stars, based on 1 article reviews
autologous cd19 car-t cell therapy - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier
anti cd19 car t cell therapy  (Kite Pharma)
86
Kite Pharma anti cd19 car t cell therapy
FMC63 and HI19α had different binding epitopes on <t>CD19.</t> a Homology models of hCD19 ECD (left), FMC63 scFv (middle), and HI19α scFv (right). b Docking mode of FMC63 and hCD19 ECD. Green, hCD19 ECD epitopes; purple, FMC63 epitopes. c Docking mode of HI19α and hCD19 ECD. Green, hCD19 ECD epitopes; purple, HI19α epitopes. d Sequence of hCD19 ECD. Gray background, predicted binding amino acid residues on hCD19 ECD with scFvs. Upper panel, interaction with HI19α; lower panel, interaction with FMC63. Red color, shared antigen epitopes; yellow color, key epitopes; green color, both shared antigen epitopes and key epitopes. e Partial interaction modes showed the non-bond interaction between scFvs and hCD19 ECD. Upper panel, HI19α scFv and hCD19 ECD; lower panel, FMC63 scFv and hCD19 ECD. Green, hCD19 ECD epitopes; purple, scFvs epitopes. f Flow cytometry analysis of the proportion of CD19 + Nalm-6 cells stained with indicated concentrations of the antibody. Left panel, HI19α antibody; right panel, FMC63 antibody. g Representative flow cytometry analysis showing the proportion of CD19 + cells on Nalm-6 cells stained with 0.017 pM HI19α and 0.042 pM FMC63
Anti Cd19 Car T Cell Therapy, supplied by Kite Pharma, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/second+generation+car+t+cell+therapies+targeting+cd19/cd19/zhu_iowis__2021__next_generation_receptors_for_the_enhanced_control_of_cell_based_immunotherapies-84-7-2
Average 86 stars, based on 1 article reviews
anti cd19 car t cell therapy - by Bioz Stars, 2026-10
86/100 stars
  Buy from Supplier
cd19 car t construct  (Celgene)
86
Celgene cd19 car t construct
FMC63 and HI19α had different binding epitopes on <t>CD19.</t> a Homology models of hCD19 ECD (left), FMC63 scFv (middle), and HI19α scFv (right). b Docking mode of FMC63 and hCD19 ECD. Green, hCD19 ECD epitopes; purple, FMC63 epitopes. c Docking mode of HI19α and hCD19 ECD. Green, hCD19 ECD epitopes; purple, HI19α epitopes. d Sequence of hCD19 ECD. Gray background, predicted binding amino acid residues on hCD19 ECD with scFvs. Upper panel, interaction with HI19α; lower panel, interaction with FMC63. Red color, shared antigen epitopes; yellow color, key epitopes; green color, both shared antigen epitopes and key epitopes. e Partial interaction modes showed the non-bond interaction between scFvs and hCD19 ECD. Upper panel, HI19α scFv and hCD19 ECD; lower panel, FMC63 scFv and hCD19 ECD. Green, hCD19 ECD epitopes; purple, scFvs epitopes. f Flow cytometry analysis of the proportion of CD19 + Nalm-6 cells stained with indicated concentrations of the antibody. Left panel, HI19α antibody; right panel, FMC63 antibody. g Representative flow cytometry analysis showing the proportion of CD19 + cells on Nalm-6 cells stained with 0.017 pM HI19α and 0.042 pM FMC63
Cd19 Car T Construct, supplied by Celgene, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/second+generation+car+t+cell+therapies+targeting+cd19/anti+bcma+car+cell+t+therapies/us12594302-1019-17-20
Average 86 stars, based on 1 article reviews
cd19 car t construct - by Bioz Stars, 2026-10
86/100 stars
  Buy from Supplier

Image Search Results


FMC63 and HI19α had different binding epitopes on CD19. a Homology models of hCD19 ECD (left), FMC63 scFv (middle), and HI19α scFv (right). b Docking mode of FMC63 and hCD19 ECD. Green, hCD19 ECD epitopes; purple, FMC63 epitopes. c Docking mode of HI19α and hCD19 ECD. Green, hCD19 ECD epitopes; purple, HI19α epitopes. d Sequence of hCD19 ECD. Gray background, predicted binding amino acid residues on hCD19 ECD with scFvs. Upper panel, interaction with HI19α; lower panel, interaction with FMC63. Red color, shared antigen epitopes; yellow color, key epitopes; green color, both shared antigen epitopes and key epitopes. e Partial interaction modes showed the non-bond interaction between scFvs and hCD19 ECD. Upper panel, HI19α scFv and hCD19 ECD; lower panel, FMC63 scFv and hCD19 ECD. Green, hCD19 ECD epitopes; purple, scFvs epitopes. f Flow cytometry analysis of the proportion of CD19 + Nalm-6 cells stained with indicated concentrations of the antibody. Left panel, HI19α antibody; right panel, FMC63 antibody. g Representative flow cytometry analysis showing the proportion of CD19 + cells on Nalm-6 cells stained with 0.017 pM HI19α and 0.042 pM FMC63

Journal: Journal of Hematology & Oncology

Article Title: Efficacy and safety of CD19 CAR T constructed with a new anti-CD19 chimeric antigen receptor in relapsed or refractory acute lymphoblastic leukemia

doi: 10.1186/s13045-020-00953-8

Figure Lengend Snippet: FMC63 and HI19α had different binding epitopes on CD19. a Homology models of hCD19 ECD (left), FMC63 scFv (middle), and HI19α scFv (right). b Docking mode of FMC63 and hCD19 ECD. Green, hCD19 ECD epitopes; purple, FMC63 epitopes. c Docking mode of HI19α and hCD19 ECD. Green, hCD19 ECD epitopes; purple, HI19α epitopes. d Sequence of hCD19 ECD. Gray background, predicted binding amino acid residues on hCD19 ECD with scFvs. Upper panel, interaction with HI19α; lower panel, interaction with FMC63. Red color, shared antigen epitopes; yellow color, key epitopes; green color, both shared antigen epitopes and key epitopes. e Partial interaction modes showed the non-bond interaction between scFvs and hCD19 ECD. Upper panel, HI19α scFv and hCD19 ECD; lower panel, FMC63 scFv and hCD19 ECD. Green, hCD19 ECD epitopes; purple, scFvs epitopes. f Flow cytometry analysis of the proportion of CD19 + Nalm-6 cells stained with indicated concentrations of the antibody. Left panel, HI19α antibody; right panel, FMC63 antibody. g Representative flow cytometry analysis showing the proportion of CD19 + cells on Nalm-6 cells stained with 0.017 pM HI19α and 0.042 pM FMC63

Article Snippet: The CD19 CAR T cells were produced by Juventas Cell Therapy Ltd (Product ID: CNCT19).

Techniques: Binding Assay, Sequencing, Flow Cytometry, Staining

Responses of all 20 R/R B-ALL patients to CNCT19 CAR T cell therapy. In this single-center, open-label, prospective clinical trial, a total of 20 patients diagnosed with resistant or refractory CD19 + B cell acute lymphoblastic leukemia received an infusion of CNCT19 CAR T cells. Responses over time of each patient are presented as a swimmer plot

Journal: Journal of Hematology & Oncology

Article Title: Efficacy and safety of CD19 CAR T constructed with a new anti-CD19 chimeric antigen receptor in relapsed or refractory acute lymphoblastic leukemia

doi: 10.1186/s13045-020-00953-8

Figure Lengend Snippet: Responses of all 20 R/R B-ALL patients to CNCT19 CAR T cell therapy. In this single-center, open-label, prospective clinical trial, a total of 20 patients diagnosed with resistant or refractory CD19 + B cell acute lymphoblastic leukemia received an infusion of CNCT19 CAR T cells. Responses over time of each patient are presented as a swimmer plot

Article Snippet: The CD19 CAR T cells were produced by Juventas Cell Therapy Ltd (Product ID: CNCT19).

Techniques:

The expansion kinetics of CAR T cells and different T cell subsets after CD19 CAR T cell infusion. a The expansion and persistence of CNCT19 CAR T cells after infusion. b The expansion and percentage of CD4 + or CD8 + T cells in peripheral blood after CAR infusion. c – d The phenotype of CD8 + T cells ( c ) or CD4 + T cells ( d ) in peripheral blood after CNCT19 CAR T cell infusion (T N , naïve T cells; T CM , central memory T cells; T EM , effective memory T cells; and T E , effector T cells)

Journal: Journal of Hematology & Oncology

Article Title: Efficacy and safety of CD19 CAR T constructed with a new anti-CD19 chimeric antigen receptor in relapsed or refractory acute lymphoblastic leukemia

doi: 10.1186/s13045-020-00953-8

Figure Lengend Snippet: The expansion kinetics of CAR T cells and different T cell subsets after CD19 CAR T cell infusion. a The expansion and persistence of CNCT19 CAR T cells after infusion. b The expansion and percentage of CD4 + or CD8 + T cells in peripheral blood after CAR infusion. c – d The phenotype of CD8 + T cells ( c ) or CD4 + T cells ( d ) in peripheral blood after CNCT19 CAR T cell infusion (T N , naïve T cells; T CM , central memory T cells; T EM , effective memory T cells; and T E , effector T cells)

Article Snippet: The CD19 CAR T cells were produced by Juventas Cell Therapy Ltd (Product ID: CNCT19).

Techniques: